Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$77.47 USD

77.47
1,021,487

-1.14 (-1.45%)

Updated Aug 7, 2025 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in TAVR procedures globally.

Zacks Equity Research

908 Devices Inc. (MASS) Soars 8.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

908 Devices Inc. (MASS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

Zacks Equity Research

Edwards Lifesciences (EW) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

Edwards' (EW) Innovation Aids Growth, Critical Care Flourishes

by Zacks Equity Research

Edwards' (EW) Surgical Structural Heart sales growth is lifted by the increased adoption of its premium products across all regions.

Zacks Equity Research

Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Shilpa Mete headshot

4 GARP Stocks to Scoop Up for Maximum Returns

by Shilpa Mete

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RACE, GWW, ALLE and EW are some stocks that hold promise.

Zacks Equity Research

Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.

Zacks Equity Research

Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes

by Zacks Equity Research

Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.

Zacks Equity Research

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Zacks Equity Research

Edwards Lifesciences (EW) Down 5.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Stock Reports for Home Depot, Linde & Walt Disney

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Linde plc (LIN) and The Walt Disney Company (DIS).

Zacks Equity Research

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls

by Zacks Equity Research

Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.

Zacks Equity Research

Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up

by Zacks Equity Research

Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.

Zacks Equity Research

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.

Zacks Equity Research

Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed

by Zacks Equity Research

Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.

Zacks Equity Research

NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.

Zacks Equity Research

Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan

by Zacks Equity Research

Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.

Zacks Equity Research

SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up

by Zacks Equity Research

SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.

Zacks Equity Research

Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised

by Zacks Equity Research

The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.

Zacks Equity Research

Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.

Zacks Equity Research

Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay

by Zacks Equity Research

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.